Acrivon Therapeutics (ACRV) Short-term Investments (2022 - 2026)

Acrivon Therapeutics (ACRV) has reported Short-term Investments for 5 consecutive years, with $63.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 42.37% year-over-year to $63.7 million; the TTM figure through Mar 2026 stood at $63.7 million (down 42.37% YoY), while the FY2025 annual figure was $77.1 million, down 44.81% from the prior year.
• Short-term Investments fell to $63.7 million in Q1 2026 per ACRV's latest filing, from $77.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $144.0 million in Q3 2024 and bottomed at $44.7 million in Q3 2022.
• Historically, Short-term Investments has averaged $99.8 million across 5 years, with a median of $95.5 million in 2025.
• Annual changes were most pronounced in 2023 — Short-term Investments soared 150.83% — and 2025, when it plunged 44.81%.
• Acrivon Therapeutics' Short-term Investments stood at $98.2 million in 2022, then decreased by 6.91% to $91.4 million in 2023, then soared by 52.73% to $139.7 million in 2024, then slumped by 44.81% to $77.1 million in 2025, then slipped by 17.4% to $63.7 million in 2026.
• Business Quant data shows ACRV's Short-term Investments at $63.7 million in Q1 2026, $77.1 million in Q4 2025, and $93.8 million in Q3 2025.